Sat Kartar Shopping Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 293 Cr.
- Current Price ₹ 186
- High / Low ₹ 238 / 124
- Stock P/E 17.0
- Book Value ₹ 43.0
- Dividend Yield 0.38 %
- ROCE 37.4 %
- ROE 29.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 34.5%
Cons
- Working capital days have increased from 28.3 days to 60.9 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 52 | 83 | 128 | 163 | 194 | |
| 49 | 78 | 118 | 149 | 169 | |
| Operating Profit | 3 | 5 | 10 | 14 | 25 |
| OPM % | 5% | 6% | 8% | 9% | 13% |
| 0 | 0 | 0 | 1 | 2 | |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 3 |
| Profit before tax | 2 | 3 | 9 | 13 | 23 |
| Tax % | 7% | 27% | 27% | 25% | 26% |
| 1 | 3 | 6 | 10 | 17 | |
| EPS in Rs | 1.99 | 3.59 | 22.54 | 6.24 | 10.96 |
| Dividend Payout % | 0% | 0% | 3% | 11% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 90% |
| TTM: | 77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 37% |
| 3 Years: | 34% |
| Last Year: | 29% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 3 | 16 | 16 |
| Reserves | 0 | 3 | 7 | 36 | 52 |
| 8 | 4 | 2 | 6 | 2 | |
| 3 | 8 | 11 | 6 | 14 | |
| Total Liabilities | 12 | 15 | 22 | 64 | 84 |
| 5 | 4 | 8 | 7 | 11 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 |
| 8 | 11 | 14 | 57 | 71 | |
| Total Assets | 12 | 15 | 22 | 64 | 84 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 7 | -5 | 0 | |||
| -3 | -0 | -9 | |||
| -3 | 34 | -1 | |||
| Net Cash Flow | 2 | 28 | -9 | ||
| Free Cash Flow | 7 | -10 | -7 | ||
| CFO/OP | 98% | -13% | 26% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 1 | 0 | 7 | 13 | 26 |
| Inventory Days | 31 | 25 | 23 | 185 | 258 |
| Days Payable | 165 | 226 | 237 | 170 | 293 |
| Cash Conversion Cycle | -134 | -200 | -208 | 29 | -9 |
| Working Capital Days | 1 | -14 | -7 | 31 | 61 |
| ROCE % | 50% | 98% | 40% | 37% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Average Ticket Size per Order INR |
|
|
| Consumer Database Size Million |
||
| Daily Unique Leads Generated Number |
||
| Number of Call / Wellness Executives Number |
||
| Number of Manufacturing Facilities (Contract/Owned) Number |
||
| Number of SKUs Number |
||
| Pincodes Covered Across India Number |
||
| Total Employee Strength Number |
||
Extracted by Screener AI
Documents
Announcements
-
Reply to Clarification- Financial results
14 May 2026 - Company clarifies omitted issue-proceeds utilization disclosure in 05-May-2026 financial results.
-
Shareholders meeting
13 May 2026 - EGM on 13 May 2026 approved preferential equity issue and convertible warrants to non-promoters.
-
Shareholders meeting
13 May 2026 - EGM approved preferential equity issue and warrants to non-promoters on May 13, 2026.
-
Analysts/Institutional Investor Meet/Con. Call Updates
9 May 2026 - Submitted H2/FY26 earnings call transcript; revenue rose 23%, EBITDA 73%, PAT 74%, with hospital expansion plans.
-
Updates
9 May 2026 - NSE granted in-principle approval for 50,400 equity shares and 27,74,400 shares from warrant conversion.
Annual reports
Concalls
-
May 2026Transcript PPT
-
May 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptPPT
-
Nov 2025Transcript PPT REC
-
Oct 2025TranscriptAI SummaryPPT
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.